BioSpace News Archive

VASCEPA ® , compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events ( MACE ) in post hoc exploratory analyses of patients with a history of CABG by 2 4% and 3 6 %, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 3 1 % Administration of VASCEPA resulted in robust absolute risk reductions of 6 . 2 % and 6 . 0 % and numbers needed to tr

- Phesgo® Can be Administered in 5 to 8 Minutes Compared with 1-2.5 Hours for the Standard Sequential IV Administration of Perjeta® and Herceptin®[1,2,3] - - Phesgo® is the First Subcutaneous Fixed-dose Combination of Two Monoclonal Antibodies Utilizing Halozyme’s ENHANZE® Technology -

The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date November 13, 2020 Time 11:30 AM (EST) Location Sir John A Macdonald Building, Room 200 144 Wellington Street, Ottawa, Ontario The media availability will also be

– Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases –

TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes

DunhamTrimmer, the global leader in business intelligence for the biocontrol, biostimulant and biofertilizer industries, announced today it has named Massimo Toni the company’s new Vice President of New Business Development.

The CHMP recommended approval of ELZONRIS for the first line treatment of adult patients with BPDCN If approved by the European Commission, ELZONRIS will be the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe

Apellis Pharmaceuticals today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology

Updated coverage decision from Novitas Solutions marks major milestone, as Company advances toward full-scale commercialization

Theralase Technologies Inc. announced today that its PDC technology has demonstrated a high kill rate in a preclinical analysis of coronavirus, Biological Safety Level (“BSL-2").